Microsomal enzyme induction and clinical aggravation of porphyria: The evaluation of human urinary 6β-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity

Journal of Clinical Pharmacology

Volumn 42, Issue 12, 2002, Pages 1374-1379

  Uejimu, Etsuko ^a   Takahashi, Kyoko ^b   Morisaki, Tomoko ^b   Takahashi, Koichi ^c   Ohno, Masako ^b   Nishida, Yuko ^a   Moriya, Masayuki ^d   Kaido, Misako ^d   Abe, Kazuo ^d   Sakoda, Saburo ^d   Yanagihara, Takehiko ^d   Kurokawa, Nobuo ^a   Azuma, Junichi ^b  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALCOHOL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450 3A4; DIAZEPAM; ESTROGEN; GLYCEROL; HYDROCORTISONE; HYDROXYCORTICOSTEROID; LIVER ENZYME; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PORPHYRIN; THIAMYLAL; VALPROIC ACID;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYMURIA; EPILEPSY; FEMALE; GENOTYPE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; MASS SPECTROMETRY; MENTAL DISEASE; PATHOGENESIS; PORPHYRIA; QUADRIPLEGIA; SEIZURE;

ADULT; ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; ENCEPHALITIS, HERPES SIMPLEX; ENZYME INDUCTION; EPILEPSY; FECES; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; MASS SPECTROMETRY; MICROSOMES; PORPHYRIAS; PORPHYRINS; QUADRIPLEGIA;

EID: 18744417229     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002042012012     Document Type: Article

References (29)

1. Sassa S: Synthesis of heme, in: Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds.), Hematology. New York: McGraw-Hill, 1990; 322-329.
2. Reynolds NC Jr, Miaka RM: Safety of anticonvulsants in hepatic porphyries. Neurology 1981;31:480-484.
3. Hahn M, Gildemeister OS, Krauss GL, Pepe JA, Lambrecht RW, Donohue S, et al: Effect of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: Potential implications for patients with acute porphyria. Neurology 1997;49:97-106.
4. Ohno M, Yamaguchi I, Saiki K, Yamamoto I, Azuma J: Specific determination of urinary 6β-hydroxycortisol and cortisol ratio by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatography B 2000;746:95-101.
5. Kaido M, Fukada K, Moriya M, Abe K, Sakoda S, Kondo M, et al: Porphyria with double errors in the heme biosynthetic pathway. J Neurology 2001;248:328-329.
6. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al: Slow N-acethyltransferase 2 genotype affects the incidence of isoniazide-refampicin-induced hepatotoxity. Int J Tuberc Lung Dis 2000;4:256-261.
7. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takeda K, et al: Effect of CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Phamacol 1999;47:450-453.
8. Zhou Q, Yamamoto I, Fukuda T, Ohno M, Sumida A, Azuma J: CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol 1999;55:43-47.
9. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al: Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-528.
10. Herbert L, Peter R, Scott E, Jacqueline FS: Seizure management in acute hepatic porphyria: Risks of valproate and clonazepam. Neurology 1980;30:588-592.
11. Reynolds NC Jr, Miska RM: Safety of anticonvulsants in hepatic porphyries. Neurology 1981;31:480-484.
12. Ono T, Johno M, Kayashima K, Omori A: Anticonvulsant syndrome with multiple symptoms, including porphyria, IgA deficiency, and liver dysfunction. J Dermatol 1990;7:684-689.
13. Chaix Y, Gencourt C, Grouteau E, Carriere JP: Acute intermittent porphyria associated with epilepsy in a child. Arch Pediatr 1997;4:971-974.
14. Bertz RJ, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258.
15. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
16. Bartoli A, Gatti G, Cipolla G, Barzaghi N, Veliz C, Fattore C, et al: A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy females volunteers. Epilepsia 1997;38:702-707.
17. Bienvenu T, Rey E, Pons G, D'Athis P, Olive G: A simple non-invasive procedure for the investigation of cytochrome P-450IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 1991;29:441-445.
18. Fleishaker JC, Pearson LK, Peters GR: Phenytoin causes a rapid increase in 6β-hydroxycortisol urinary excretion in humans: A putative measure of CYP3A induction. J Pharm Sci 1995;84:292-294.
19. Kuhnz W, Lofberg B: Urinary excretion of 6β-hydroxycortisol in women during treatment with different oral contraceptive formulations. J Steroid Biochem Mol Biol 1995;55:129-133.
20. Moreland TA, Park BK, Rylance GW: Microsomal enzyme induction in children: The influence of carbamazepine treatment on antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity. Br J Clin Pharmacol 1982;14:861-865.
21. Ohnhaus EE, Gerber-Taras E, Park BK: Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur J Clin Pharmacol 1983;24:247-250.
22. Rost KL, Brosicke H, Heynemeyer G, Roots I: Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994;20:1204-1212.
23. Rost KL, Mansmann U, Roots I: Urinary 6β-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. Int J Clin Pharmacol Ther 1997;35:14-18.
24. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
25. Tang C, Kassahun K, McIntosh IS, Brunner J, Rodrigues AD: Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry and its application for estimating hepatic CYP3A induction. J Chromatography B 2000;742:303-313.
26. Biagini R, Tignani R, Fifi AR, Nappini L: Acute intermittent porphyria and epilepsy. Arch Dis Child 1979;54:644-645.
27. D'Alessadro R, Rocchi E, Cristina E, Cassanelli M, Benassi G, Pizzino D, et al:: Safety of valproate in porphyria cutanea tarda. Epilepsia 1988;29:159-162.
28. Kashuba DMA, Nafziger NA: Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-218.
29. Jover R, Hoffmann F, Scheffler-Koch V, Lindberg RL: Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital. Eur J Biochem 2000;267:7128-7137.